NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
Board of Directors Announces CEO Succession Plan PORTLAND, Ore.–(BUSINESS WIRE)–NW Natural Holding Company (NYSE: NWN) (NW Natural Holdings) and NW Natural... Read more.
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting
Advancing oncology and bridging healthcare gaps NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced its significant presence at this year’s American... Read more.
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ASCO—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology... Read more.
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
Preliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed... Read more.
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data... Read more.
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress... Read more.
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
HOUSTON–(BUSINESS WIRE)–Stellar Bancorp, Inc. (the “Company”) (NYSE: STEL) today announced that on May 23, 2024, its Board of Directors declared... Read more.
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level... Read more.
NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
Adults with blood cancers receiving peripheral blood stem cell transplant exhibited excellent survival rates and low incidence of life-threatening graft-versus-host-disease... Read more.
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
First-in-human data for potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in treatment of metastatic colorectal cancer to... Read more.